Day: March 12, 2026

After more than 100 development iterations, Hop-on subsidiary Digitalage has entered controlled production deployment — with live creator broadcasting underway, Newsroom OS active in TestFlight, and full public launch approaching as the platform completes its final pre-release validation phase TEMECULA, Calif., March 12, 2026 (GLOBE NEWSWIRE) — Hop-on, Inc. (OTC: HPNN), through its subsidiary Digitalage, today announced that its live streaming platform and Newsroom OS journalism intelligence system have entered controlled production deployment — with live creator broadcasting underway, enterprise newsroom access active in TestFlight, and the company’s full public platform launch approaching. The announcement marks the conclusion of an intensive development phase spanning more than 100 platform iterations — a deliberate, disciplined...

New single-family homes in the Lago and Sol Collections feature open floor plans and resort-style amenities PUNTA GORDA, Fla., March 12, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the debut of new single-family home designs at Regency at Babcock Ranch, a premier 55+ active-adult community by Toll Brothers, in Punta Gorda, Florida. The community has unveiled four new larger home designs in the Lago and Sol Collections within the highly sought-after Babcock Ranch master plan.The Lago and Sol Collections at Regency at Babcock Ranch feature an array of stunning single-family homes designed with active adult lifestyles in mind. The new Pinellas and Volusia home designs in the Lago Collection provide expanded options for up to 4 bedrooms, 3.5 bathrooms, 2-car...

Sampo plc, stock exchange release, 12 March 2026 at 5:10 pm EET Sampo to launch a new long-term incentive scheme for 2026–2028 The Board of Directors of Sampo plc has today decided to adopt a performance based long-term incentive scheme for the Group Executive Committee (including the Group CEO) and other senior leaders and key employees of Sampo Group. The scheme is based on the same structure as the previous long-term incentive schemes launched in Sampo in 2024 and 2025. Sampo aims to ensure that management incentives are aligned with the shareholders’ interests and Group strategy. The long-term incentive scheme 2026 (LTI 2026) covers approximately one hundred (100) senior leaders and key employees, including the Group CEO and other members of the Group Executive Committee, whose efforts and abilities have a direct impact on Sampo Group’s...

Octopus AIM VCT 2 plc Annual Report for the year ended 30 November 2025 and Notice of Meeting Further to the announcement of annual results for the year ended 30 November 2025, Octopus AIM VCT 2 plc (the ‘Company’) announces that the Annual Report has been posted or otherwise made available to shareholders. A copy of the Annual Report is also available to view on the Company’s website at http://www.octopusinvestments.com The Annual Report includes the Notice of Meeting for the Annual General Meeting of the Company to be held on 19 May 2026. The Annual Report, together with the Form of Proxy, has been submitted to the Financial Conduct Authority’s Electronic Submission System and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism For further information please contact: Andrew HumphriesOctopus Company...

Artea Bankas, AB (“Artea Bankas” or the “Bank”) was informed by Tesonet Global, UAB (“Tesonet Global”) on March 12, 2026, of its intention to increase the ownership stake in the Bank to up to 31.68% (including the stake, which is currently held by Tesonet Global). For this purpose, Tesonet Global has entered into the transactions, as described below. On March 12, 2026, Tesonet Global executed and closed the share sale-purchase agreement with Willgrow UAB (“Willgrow”), acquiring a 2.52% stake in the Bank at a purchase price of EUR 1.1012 per share. This initial transaction brings Tesonet Global’s current post-closing ownership to 9.86%. On the same date, Tesonet Global also signed conditional agreements to acquire additional shares in Artea Bankas from multiple existing shareholders. These include agreements to acquire all shares...

Chassieu, March 12, 2026 (GLOBE NEWSWIRE) — Amoéba receives its first order from Koppert and confirms its transformation into a commercial company Chassieu (France), 11 March 2026 – 6:00 pm – Amoéba (FR0011051598 – ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces its first order from its partner Koppert, world leader in biocontrol. Amoéba thus becomes a true commercial company, whose biocontrol activities are now structured around its subsidiary Green 4 Agro, headed by Jean-Marc PETAT, former director of the Company and expert in the sector. A first order that marks a new phase in Amoéba’s history The first deliveries of this order, which is part of the distribution agreement signed with Koppert in June 2025 covering...

Invalda INVL, the leading Baltic asset management group, on 12 March entered into an agreement with Tesonet Global under which it is selling 7,987,158 shares of Artea Bank, representing 1.22% of the bank’s share capital. Invalda INVL currently holds a 19.94% stake in Artea Bank. “Tesonet is one of the most successful Lithuanian businesses operating globally. We believe that their engagement and growing investments in Artea will drive faster development of the bank, with greater focus on technology and customers,” – Darius Šulnis, CEO of Invalda INVL, says. As Artea Bank executes share buyback programs and may decide to cancel the repurchased shares, Invalda INVL has decided to slightly reduce its stake to ensure it does not exceed the 20% threshold set in the approval of the European Central Bank. On the closing date,...

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company’s Scientific Advisory Board. Dr. Taku Kambayashi and Dr. Selvakumar Subbian bring world-class expertise in immunology and infectious disease, directly aligned with the Company’s therapeutic focus and clinical development roadmap. The Company intends to disclose one, final accepted member of its initial Scientific...